[go: up one dir, main page]

FR2870241B1 - Facteur de viabilite des cones derive des batonnets ou rdcvf et applications - Google Patents

Facteur de viabilite des cones derive des batonnets ou rdcvf et applications

Info

Publication number
FR2870241B1
FR2870241B1 FR0405224A FR0405224A FR2870241B1 FR 2870241 B1 FR2870241 B1 FR 2870241B1 FR 0405224 A FR0405224 A FR 0405224A FR 0405224 A FR0405224 A FR 0405224A FR 2870241 B1 FR2870241 B1 FR 2870241B1
Authority
FR
France
Prior art keywords
batonnets
rdcvf
viability
factor
applications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0405224A
Other languages
English (en)
Other versions
FR2870241A1 (fr
Inventor
Carlos Alvarez
Thierry Leveillard
Jose Alain Sahel
Said Saddek Mohand
David Hicks
Olivier Poch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Novartis AG
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Novartis AG
Priority to FR0405224A priority Critical patent/FR2870241B1/fr
Priority to PCT/EP2005/005184 priority patent/WO2005113586A2/fr
Priority to US11/596,327 priority patent/US20090215679A1/en
Publication of FR2870241A1 publication Critical patent/FR2870241A1/fr
Priority to US12/985,741 priority patent/US20110105411A1/en
Priority to US13/716,290 priority patent/US9353162B2/en
Application granted granted Critical
Publication of FR2870241B1 publication Critical patent/FR2870241B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0405224A 2004-05-13 2004-05-13 Facteur de viabilite des cones derive des batonnets ou rdcvf et applications Expired - Fee Related FR2870241B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0405224A FR2870241B1 (fr) 2004-05-13 2004-05-13 Facteur de viabilite des cones derive des batonnets ou rdcvf et applications
PCT/EP2005/005184 WO2005113586A2 (fr) 2004-05-13 2005-05-12 Proteines associees a des maladies
US11/596,327 US20090215679A1 (en) 2004-05-13 2005-05-12 Disease-associated proteins
US12/985,741 US20110105411A1 (en) 2004-05-13 2011-01-06 Disease-Associated Proteins
US13/716,290 US9353162B2 (en) 2004-05-13 2012-12-17 Disease-associated proteins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0405224A FR2870241B1 (fr) 2004-05-13 2004-05-13 Facteur de viabilite des cones derive des batonnets ou rdcvf et applications

Publications (2)

Publication Number Publication Date
FR2870241A1 FR2870241A1 (fr) 2005-11-18
FR2870241B1 true FR2870241B1 (fr) 2015-02-27

Family

ID=34945897

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0405224A Expired - Fee Related FR2870241B1 (fr) 2004-05-13 2004-05-13 Facteur de viabilite des cones derive des batonnets ou rdcvf et applications

Country Status (3)

Country Link
US (3) US20090215679A1 (fr)
FR (1) FR2870241B1 (fr)
WO (1) WO2005113586A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004113494A2 (fr) 2003-05-21 2004-12-29 Avigen, Inc. Procedes de production de preparations de virions aav recombinants sensiblement exemptes de capsides vides
EP2027889A1 (fr) * 2007-06-05 2009-02-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveau facteur de viabilité neuronale et son utilisation
US9567382B2 (en) 2008-04-15 2017-02-14 Genzyme Corporation Methods to produce rod-derived cone viability factor (RdCVF)
ES2548980T3 (es) 2008-09-10 2015-10-22 Inserm - Institut National De La Santé Et De La Recherche Médicale Factor de viabilidad neuronal y uso del mismo
ES2677564T3 (es) * 2009-06-19 2018-08-03 Inserm (Institut National De La Santé Et De La Recherche Medicale) Método y composición farmacéutica para su uso en el tratamiento de trastornos neurodegenerativos
DK2797613T3 (da) 2011-10-27 2020-03-02 Wellstat Ophthalmics Corp Vektorer, der koder for rod-derived cone viability-faktor
US10004780B2 (en) 2012-10-17 2018-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD)
CA3025977A1 (fr) 2016-10-11 2018-04-19 Wellstat Ophthalmics Corporation Proteine de fusion entre un facteur de viabilite de cone derive d'une tige courte et un peptide hydrophile

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223724B1 (en) * 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
FR2823221B1 (fr) * 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
AU2003225544A1 (en) * 2002-02-04 2003-09-02 Novartis Ag Recombinant bovine immunodeficiency virus based gene transfer system
US20060275794A1 (en) * 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US20070259820A1 (en) * 2006-05-03 2007-11-08 The Regents Of The University Of Michigan Methods and reagents for activating heat shock protein 70
US8193153B2 (en) * 2007-12-06 2012-06-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Trophic factor for the treatment of retinal degenerative diseases
ES2548980T3 (es) * 2008-09-10 2015-10-22 Inserm - Institut National De La Santé Et De La Recherche Médicale Factor de viabilidad neuronal y uso del mismo

Also Published As

Publication number Publication date
WO2005113586A3 (fr) 2006-04-27
WO2005113586A2 (fr) 2005-12-01
US20130102544A1 (en) 2013-04-25
US20110105411A1 (en) 2011-05-05
US9353162B2 (en) 2016-05-31
US20090215679A1 (en) 2009-08-27
FR2870241A1 (fr) 2005-11-18

Similar Documents

Publication Publication Date Title
DE602005015349D1 (de) Verbesserte kautschukmodifizierte monovinyliden-aromapolymere und daraus hergestellte erzeugnisse
EP1915670A4 (fr) Suivi et synchronisation des modifications partielles d'articles
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
EP1796155A4 (fr) Procédé de formation de perle et perle de brasage
EP1976548A4 (fr) Fragments de vip et méthodes d'utilisation
IL187303A0 (en) Methods of prepering 3 - cyano - quinolines and intermediates made thereby
DE602005008514D1 (de) Navigationssystem und Verkersprognoseverfahren
EP1848351A4 (fr) Implants vertebraux percutanes et methodes associees
EP1803799A4 (fr) Formule de lubrifiant et formule d antioxydant
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
BRPI0509054A (pt) óculos e método de fabricação dos mesmos
EP1938538A4 (fr) Procede de mappage de sous-porteuse variable et son dispositif
EP1713503A4 (fr) Inhibition du facteur b et de la voie du complement alternative et procedes associes
EP1746902A4 (fr) Chromatographie d'affinite multi-lectine et ses utilisations
EP1846325A4 (fr) Hydroxyapatite de dimensions et de morphologie regulables
GB0621897D0 (en) Centrifugal pumps and methods of making and using same
EP1945819A4 (fr) Profils d'expression génique et procédés d'utilisation
EP2520278A4 (fr) Moyens d'élimination des goudrons de tabac et composition contenant ces moyens
DE602006006710D1 (de) Herstellung von polytrimethylenetherglykol und copolymeren davon
DE602006006861D1 (de) Herstellung von polytrimethylenetherglykol und copolymeren davon
EP1812012A4 (fr) Inhibiteurs de proteine-tyrosine-phosphatase et methodes d'utilisation de ceux-ci
FR2870241B1 (fr) Facteur de viabilite des cones derive des batonnets ou rdcvf et applications
ATE468342T1 (de) Azolopyridin-2-on-derivate als inhibitoren von lipasen und phospholipasen
FR2867178B1 (fr) Composant micromecanique et procede de fabrication de ce composant
EP1772148A4 (fr) Inhibiteurs de la lipase

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

ST Notification of lapse

Effective date: 20230105